Document:

EX-10.1

 Exhibit 10.1 

SUBSCRIPTION AGREEMENT 
 CytoDyn Inc. 

1111 Main Street, Suite 660 
 Vancouver, Washington 98660 

Ladies and Gentlemen: 
 1. Subscription. The undersigned
(the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from CytoDyn Inc., a Delaware corporation (the “Company”) the number of shares of common stock, $0.001 par value, of the Company (the
“Common Stock”) set forth on the signature page hereof at a purchase price of $1.00 (the “Subscribed Shares”), with a minimum investment of $250,000 (“Minimum Investment Amount”), or such lesser amount accepted by the
Company in its sole discretion. In addition, the Purchaser shall also receive warrants, substantially in the form attached hereto as Exhibit A (the “Warrants” and together with the shares of Common Stock issuable
upon exercise of the Warrants (the “Warrant Shares”) and the Subscribed Shares, collectively, the “Securities”), to purchase a number of shares of Common Stock equal to 25% of the number of Subscribed Shares. The Warrants will be
exercisable for Warrant Shares for a 5-year period commencing at the Closing (as defined below) at an exercise price of $1.00 per share. 

2. The Offering. This subscription is submitted to you in accordance with and subject to the terms and conditions described in this Subscription
Agreement relating to the offering (the “Offering”) by the Company of Subscribed Shares and related Warrants. The closing of the Offering to which this Subscription Agreement relates (the “Closing”) may be scheduled by the
Company at any time after the execution of this Subscription Agreement. Additional Securities may have been and may continue to be offered and sold from time to time in the Offering, until the date on which the Offering is concluded, through
additional closings conducted by the Company with respect to those additional Securities sold. 
 3. Payment. The Purchaser will immediately make a
wire transfer payment to the Company pursuant to the instructions included herein in the full amount of the purchase price of the Securities being subscribed for hereby. Wire transfer instructions are set forth on the Subscription Instructions
included on the last page hereof under the heading “To subscribe for Securities in the private offering of CytoDyn Inc.” Together with a wire transfer (or, subject to the Company’s approval in its sole discretion in lieu of a wire
transfer, a check) for the full purchase price, the Purchaser is delivering a completed and executed omnibus Signature Page to this Subscription Agreement and an initialed Accredited Investor Certification. 

4. Acceptance of Subscription. The Purchaser understands and agrees that the Company, in its sole discretion, reserves the right to accept or reject
this or any other subscription for Securities, in whole or in part, notwithstanding prior receipt by the Purchaser of notice of acceptance of this subscription. The Company shall have no obligation hereunder, including the issuance of the Subscribed
Shares and the Warrants, until the Company shall execute and deliver to the Purchaser an executed copy of this Subscription Agreement. If this subscription is rejected in whole or the Offering of Securities is terminated, all funds received from the
Purchaser will be returned without interest or offset, and this Subscription Agreement shall thereafter be of no further force or effect. If this subscription is rejected in part, the funds for the rejected portion of this subscription will be
returned without interest or offset, and this Subscription Agreement will continue in full force and effect to the extent this subscription was accepted. 

 5. Restrictions on Transfer. 

(a) The Purchaser understands and agrees that the Securities are subject to the transfer restrictions specified herein and in the Warrants, and
that the Securities have not been registered under the Securities Act or the securities laws of any state or other jurisdiction; accordingly, the Securities (including the Warrant Shares) must be held indefinitely unless they are subsequently
registered or unless, in the opinion of counsel reasonably acceptable to the Company, a sale or transfer may be made in compliance with the provisions of this Subscription Agreement and the Warrants, as the case may be, and without registration
under United States securities laws and the applicable securities laws of any state or other jurisdiction. 
 (b) The Purchaser further
agrees that legends will be placed on the Securities restricting the transfer thereof, and that appropriate notations will be made in the Company’s stock books and stop transfer instructions placed with the transfer agent of the Common Stock,
each in a manner generally consistent with the foregoing. 
 (c) The Purchaser is aware of the provisions of Rule 144 that, in substance,
permit limited public resale of “restricted securities” acquired by non-affiliates of the issuer thereof, directly or indirectly, from the issuer (or from an affiliate of such issuer), in a non-public offering subject to the satisfaction of certain conditions, if applicable, including, among other things, the availability of certain public information about the Company and the resale occurring not less
than six (6) months after the party has purchased and paid for the securities to be sold. 
 (d) The Purchaser further understands that
at the time the Purchaser wishes to sell Securities (including any Warrant Shares issued or issuable upon exercise of the Warrants) there may be no public market upon which to make such a sale, and that, even if such a public market then exists, the
Company may not have filed all reports and other materials required under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Form 8-K reports, during the preceding 12
months, and that, in such event, because the Company is a former “shell company” as contemplated under paragraph (i) of Rule 144, Rule 144 will not be available to the Purchaser. 

(e) The Purchaser further understands that, because the Company is a former “shell company” as contemplated under paragraph
(i) of Rule 144, regardless of the amount of time that the Purchaser holds the Securities, sales of the Securities may only be made under Rule 144 upon the satisfaction of certain conditions, including that the Company has filed with the SEC,
during the 12 months preceding the sale, all quarterly and annual reports required under the Securities Exchange Act of 1934, as amended; and that, accordingly, any restrictive legends placed on the Securities cannot be removed except in
connection with an actual sale that is subject to an effective registration statement under, or an applicable exemption from the registration requirements of, the Securities Act, and “blanket” removals of any such restrictive legends will
not be possible. 

  
 2 

 (f) The Purchaser further understands that in the event all of the requirements of Rule 144
are not satisfied, registration under the Securities Act, compliance with Regulation A promulgated under the Securities Act, or some other registration exemption will be required; and that, notwithstanding the fact that Rule 144 is not exclusive,
the staff of the SEC has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rule 144 will have a substantial burden of proof in establishing that an
exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. 

6. Representations and Warranties. 
 The
Purchaser hereby acknowledges, represents, warrants, and agrees as follows: 
 (a) None of the Securities offered hereby are registered under
the Securities Act or the securities laws of any state or other jurisdiction. The Purchaser understands that the offering and sale of the Securities (including the issuance of Warrant Shares upon exercise of the Warrants) is intended to be exempt
from registration under the Securities Act, by virtue of Section 4(a)(2) thereof and the provisions of Regulation D (“Regulation D”) as promulgated by the SEC thereunder, based, in part, upon the representations, warranties and
agreements of the Purchaser contained in this Subscription Agreement. 
 (b) Prior to the execution of this Subscription Agreement, the
Purchaser and the Purchaser’s attorney, accountant, purchaser representative and/or tax adviser, if any (collectively, the “Advisers”), have received all documents requested by the Purchaser, have carefully reviewed them and
understand the information contained therein. 
 (c) Neither the SEC nor any state securities commission or other regulatory authority has
approved the Subscribed Shares, the Warrants or the Warrant Shares, or passed upon or endorsed the merits of the offering of securities or confirmed the accuracy or determined the adequacy of the Offering. The Offering has not been reviewed by any
federal, state or other regulatory authority. 
 (d) All documents, records, and books pertaining to the investment in the Securities have
been made available for inspection by the Purchaser and his, her or its Advisers, if any. 
 (e) The Purchaser and the Purchaser’s
Advisers, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or persons acting on behalf of the Company concerning the Offering and sale of the Securities and the business, financial condition and results
of operations of the Company, and all such questions have been answered to the full satisfaction of the Purchaser and Advisers, if any. 

(f) In evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or information (oral or
written) other than as stated in this Subscription Agreement. 

  
 3 

 (g) The Purchaser is unaware of, is in no way relying on, and did not become aware of the
Offering of the Securities through or as a result of, any form of general solicitation or general advertising including, without limitation, any article, notice, advertisement or other communication published in any newspaper, magazine or similar
media or broadcast over television, radio or the Internet (including, without limitation, internet “blogs,” bulletin boards, discussion groups and social networking sites) in connection with the Offering and sale of the Securities and is
not subscribing for the Securities and did not become aware of the Offering of the Securities through or as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by, a person not previously
known to the Purchaser in connection with investments in securities generally. 
 (h) The Purchaser, together with its Advisers, if any, has
such knowledge and experience in financial, tax, and business matters and, in particular, investments in securities, so as to enable the Purchaser to utilize the information made available in connection with the Offering to evaluate the merits and
risks of an investment in the Securities and the Company and to make an informed investment decision with respect thereto. 
 (i) The
Purchaser has taken no action that would give rise to any claim by any person for brokerage commissions, finders’ fees or the like relating to this Subscription Agreement or the transactions contemplated hereby. 

(j) The Purchaser is not relying on the Company or any of its employees or agents with respect to the legal, tax, economic and related
considerations of an investment in the Securities, and the Purchaser has relied on the advice of, or has consulted with, only its own Advisers. 

(k) The Purchaser is acquiring the Securities (including, upon exercise of the Warrants, the Warrant Shares) solely for such Purchaser’s
own account for investment purposes only and not with a view to or intent of resale or distribution thereof, in whole or in part. The Purchaser has no agreement or arrangement, formal or informal, with any person to sell or transfer all or any part
of the Subscribed Shares, the Warrants or the Warrant Shares, and the Purchaser has no plans to enter into any such agreement or arrangement. 

(l) The Purchaser understands and agrees that the Purchaser must bear the substantial economic risks of the investment in the Securities
(including, upon exercise of the Warrants, the Warrant Shares) indefinitely because none of the Securities may be sold, hypothecated or otherwise disposed of unless subsequently registered under the Securities Act and the applicable securities laws
of any state or other jurisdiction or an exemption from such registration is available. Legends shall be placed on the Securities to the effect that they have not been registered under the Securities Act or the securities laws of any state or other
jurisdiction and appropriate notations thereof will be made in the Company’s stock books. Stop transfer instructions will be placed with the transfer agent of the Securities. There will not be any assurance that such Securities will be freely
transferable at any time in the foreseeable future. 
 (m) The Purchaser has adequate means of providing for such Purchaser’s current
financial needs and foreseeable contingencies and has no need for liquidity from its investment in the Securities for an indefinite period of time. 

(n) The Purchaser is aware that an investment in the Securities is high risk, involving a number of very significant risks and has carefully
read and considered the matters set forth under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC on July 30, 2021 (including the documents incorporated by reference
therein) and in any subsequent reports filed with the SEC (the “SEC Filings”), and, in particular, acknowledges that the Company (i) has significant operating losses since inception, no revenues to date, and limited assets,
(ii) is engaged in a highly competitive business and (iii) will need additional capital, resulting in dilution to the Purchaser if the Purchaser is not able to participate in future offerings. 

  
 4 

 (o) The Purchaser meets the requirements of at least one of the suitability standards for an
“accredited investor” as that term is defined in Regulation D and as set forth on the Accredited Investor Certification contained herein. 

(p) The Purchaser (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to
execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof; (ii) if a corporation, partnership, or limited liability company or partnership, or
association, joint stock company, trust, unincorporated organization or other entity, represents that such entity was not formed for the specific purpose of acquiring the Securities, such entity is duly organized, validly existing and in good
standing under the laws of the state of its organization, the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of state law or its charter or other organizational documents, such entity has
full power and authority to execute and deliver this Subscription Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the securities constituting the Securities, the
execution and delivery of this Subscription Agreement has been duly authorized by all necessary action, this Subscription Agreement has been duly executed and delivered on behalf of such entity and is a legal, valid and binding obligation of such
entity; or (iii) if executing this Subscription Agreement in a representative or fiduciary capacity, represents that it has full power and authority to execute and deliver this Subscription Agreement in such capacity and on behalf of the
subscribing individual, ward, partnership, trust, estate, corporation, or limited liability company or partnership, or other entity for whom the Purchaser is executing this Subscription Agreement, and such individual, partnership, ward, trust,
estate, corporation, or limited liability company or partnership, or other entity has full right and power to perform pursuant to this Subscription Agreement and make an investment in the Company, and represents that this Subscription Agreement
constitutes a legal, valid and binding obligation of such entity. The execution and delivery of this Subscription Agreement will not violate or be in conflict with any order, judgment, injunction, agreement or controlling document to which the
Purchaser is a party or by which it is bound. 
 (q) The Purchaser and the Purchaser’s Advisers, if any, have had the opportunity to
obtain any additional information, to the extent the Company has such information in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy of the information contained in the SEC Filings and all
documents received or reviewed in connection with the purchase of the Securities and have had the opportunity to have representatives of the Company provide them with such additional information regarding the terms and conditions of this particular
investment and the financial condition, results of operations, and business of the Company deemed relevant by the Purchaser or the Purchaser’s Advisers, if any, and all such requested information, to the extent the Company had such information
in its possession or could acquire it without unreasonable effort or expense, has been provided to the full satisfaction of the Purchaser and Advisers, if any. 

  
 5 

 (r) Any information which the Purchaser has heretofore furnished or is furnishing herewith
to the Company is complete and accurate and may be relied upon by the Company in determining the availability of an exemption from registration under federal and state securities laws in connection with the Offering and sale of the Securities. The
Purchaser further represents and warrants that it will notify and supply corrective information to the Company immediately upon the occurrence of any change therein occurring prior to the Company’s issuance of the Securities. 

(s) The Purchaser has significant prior investment experience, including investment in non-listed and non-registered securities. The Purchaser is knowledgeable about investment considerations in development-stage companies with limited operating histories. The Purchaser has a sufficient net worth to sustain a loss
of its entire investment in the Company in the event such a loss should occur. The Purchaser’s overall commitment to investments which are not readily marketable is not excessive in view of the Purchaser’s net worth and financial
circumstances and the purchase of the Securities will not cause such commitment to become excessive. The investment in the Securities is a suitable one for the Purchaser. 

(t) The Purchaser is satisfied that the Purchaser has received adequate information with respect to all matters which the Purchaser or the
Purchaser’s Advisers, if any, consider material to a decision to make this investment. The Purchaser is relying on the Purchaser’s own examination, together with the Purchaser’s Advisers, if any, of the Company and the terms of the
Offering and sale of the Securities, including the merits and risks involved, in making an investment decision. 
 (u) The Purchaser
acknowledges that any estimates or forward-looking statements or projections included in the SEC Filings (including the documents incorporated by reference therein) were prepared by the Company in good faith but that the attainment of any such
projections, estimates or forward-looking statements cannot be guaranteed by the Company and should not be relied upon. 
 (v) No oral or
written representations have been made, or oral or written information furnished, to the Purchaser or the Purchaser’s Advisers, if any, in connection with the Offering which are in any way inconsistent with the information contained in this
Subscription Agreement. 
 (w) Within five (5) days after receipt of a request from the Company, the Purchaser will provide such
information and deliver such documents as may reasonably be necessary to comply with any and all laws and regulations to which the Company is subject. 

(x) THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OR
OTHER JURISDICTION. THE SECURITIES ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED
OR RESOLD EXCEPT AS PERMITTED UNDER SAID ACT AND SUCH LAWS PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. THE SECURITIES HAVE NOT BEEN RECOMMENDED, APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION
OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR ADEQUACY OF THIS SUBSCRIPTION AGREEMENT. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL. 

  
 6 

 (y) The Purchaser acknowledges and agrees that the Securities have not been registered under
the Securities Act of 1933, as amended, and that the Company has no present intention or obligation to so register the Securities, or any portion thereof, in the future. 

(z) (For ERISA plans only) The fiduciary of the ERISA plan (the “Plan”) represents that such fiduciary has been informed of
and understands the Company’s investment objectives, policies and strategies, and that the decision to invest “plan assets” (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require
diversification of plan assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (1) is responsible for the decision to invest in the Company; (2) is independent of the Company or any of its affiliates;
(3) is qualified to make such investment decision; and (4) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation of the Company or any of its affiliates. 

(aa) The Purchaser should check the Office of Foreign Assets Control (“OFAC”) website at <http://www.treas.gov/ofac> before
making the following representations. The Purchaser represents that the amounts invested by it in the Company in the Offering were not and are not directly or indirectly derived from activities that contravene federal, state or international
laws and regulations, including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by OFAC prohibit, among other things, the engagement in transactions with, and the provision of services to, certain
foreign countries, territories, entities and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found on the OFAC website at <http://www.treas.gov/ofac>. In addition, the programs administered by OFAC
(the “OFAC Programs”) prohibit dealing with individuals1 or entities in certain countries regardless of whether such individuals or entities appear on the OFAC lists. 

(bb) To the best of the Purchaser’s knowledge, none of: (1) the Purchaser; (2) any person controlling or controlled by the
Purchaser; (3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for whom the Purchaser is acting as agent or nominee in connection with this investment is a country,
territory, individual or entity named on an OFAC list, or a person or entity prohibited under the OFAC Programs. Please be advised that the Company may not accept any amounts from a prospective investor if such prospective investor cannot make the
representation set forth in the preceding paragraph. The Purchaser agrees to promptly notify the Company should the Purchaser become aware of any change in the information set forth in these representations. The Purchaser understands and
acknowledges that, by law, the Company may be obligated to “freeze the account” of the Purchaser, either by prohibiting additional subscriptions from the Purchaser, declining any redemption requests and/or segregating the assets in the
account in compliance with governmental regulations. The Purchaser further acknowledges that the Company may, by written notice to the Purchaser, suspend the redemption rights, if any, of the Purchaser if the Company reasonably deems it necessary to
do so to comply with anti-money laundering regulations applicable to the Company or any of the Company’s other service providers. These individuals include specially designated nationals, specially designated narcotics traffickers and other
parties subject to OFAC sanctions and embargo programs. 
  

	1 	 These individuals include specially designated nationals, specially designated narcotics traffickers and other
parties subject to OFAC sanctions and embargo programs. 

  
 7 

 (cc) To the best of the Purchaser’s knowledge, none of: (1) the Purchaser;
(2) any person controlling or controlled by the Purchaser; (3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for whom the Purchaser is acting as agent or
nominee in connection with this investment is a senior foreign political figure,2 or any immediate family3 member or close associate4 of a senior
foreign political figure, as such terms are defined in the footnotes below. 
 (dd) If the Purchaser is affiliated with a non-U.S. banking institution (a “Foreign Bank”), or if the Purchaser receives deposits from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser
represents and warrants to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address, in a country in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank
maintains operating records related to its banking activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the Foreign Bank to conduct banking activities; and (4) the Foreign Bank does not provide
banking services to any other Foreign Bank that does not have a physical presence in any country and that is not a regulated affiliate. 
 7.
Indemnification. The Purchaser agrees to indemnify and hold harmless the Company and its respective officers, directors, employees, agents, control persons and affiliates from and against all losses, liabilities, claims, damages, costs, fees
and expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating, preparing or defending against any litigation commenced or threatened) based upon or arising out of any actual or alleged false acknowledgment,
representation or warranty, or misrepresentation or omission to state a material fact, or breach by the Purchaser of any covenant or agreement made by the Purchaser herein or in any other document delivered in connection with this Subscription
Agreement. 
 8. Irrevocability; Binding Effect. The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the
Purchaser, except as required by applicable law, and that this Subscription Agreement shall survive the death or disability of the Purchaser and shall be binding upon and inure to the benefit of the parties and their heirs, executors,
administrators, successors, legal representatives, and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder shall be joint and several and the agreements, representations, warranties, and
acknowledgments herein shall be deemed to be made by and be binding upon each such person and such person’s heirs, executors, administrators, successors, legal representatives, and permitted assigns. 

 

	2 	 A “senior foreign political figure” is defined as a current or former senior official in the
executive, legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of a foreign government-owned corporation. In
addition, a “senior foreign political figure” includes any corporation, business or other entity that has been formed by, or for the benefit of, a senior foreign political figure. 

	3 	 “Immediate family” of a senior foreign political figure typically includes the figure’s parents,
siblings, spouse, children and in-laws. 

	4 	 A “close associate” of a senior foreign political figure is a person who is widely and publicly known
to maintain an unusually close relationship with the senior foreign political figure, and includes a person who is in a position to conduct substantial domestic and international financial transactions on behalf of the senior foreign political
figure. 

  
 8 

 9. Modification. This Subscription Agreement shall not be modified or waived except by an instrument
in writing signed by the party against whom any such modification or waiver is sought. 
 10. Notices. Any notice or other communication required or
permitted to be given hereunder shall be in writing and shall be mailed by certified mail, return receipt requested, or delivered against receipt to the party to whom it is to be given (a) if to the Company, at the address set forth above, or
(b) if to the Purchaser, at the address set forth on the signature page hereof (or, in either case, to such other address as the party shall have furnished in writing in accordance with the provisions of this Section 10). Any notice or
other communication given by certified mail shall be deemed given at the time of certification thereof, except for a notice changing a party’s address which shall be deemed given at the time of receipt thereof. If any notice is delivered by fax
or email to a party, it will be deemed to have been delivered on the date the fax or email thereof is actually received, provided the original thereof is sent by certified mail, in the manner set forth above, within twenty-four (24) hours after
the fax or email is sent. 
 11. Assignability. This Subscription Agreement and the rights, interests and obligations hereunder are not transferable
or assignable by the Purchaser and the transfer or assignment of the Subscribed Shares, the Warrants or the Warrant Shares, as the case may be, shall be made only in accordance with the respective requirements of this Subscription Agreement, the
Warrants and all applicable laws. Any purported transfer or assignment in violation of this Section 11 shall be null and void. 
 12. Applicable Law.
This Subscription Agreement shall be governed by and construed in accordance with the laws of the State of New York applicable to contracts to be wholly performed within said State. 

13. Arbitration. The parties agree to submit all controversies to arbitration in accordance with the provisions set forth below and understand that:

 (a) Arbitration is final and binding on the parties. 

(b) The parties are waiving their right to seek remedies in court, including the right to a jury trial. 

(c) Pre-arbitration discovery is generally more limited and different from court proceedings. 

(d) The arbitrator’s award is not required to include factual findings or legal reasoning and any party’s right to appeal or to seek
modification of rulings by arbitrators is strictly limited. 
 (e) The panel of arbitrators will typically include a minority of arbitrators
who were or are affiliated with the securities industry. 

  
 9 

 (f) All controversies which may arise between the parties concerning this Subscription
Agreement shall be determined by arbitration in New York, New York. Judgment on any award of any such arbitration may be entered in any court having jurisdiction of the person or persons against whom such award is rendered. Any notice of such
arbitration or for the confirmation of any award in any arbitration shall be sufficient if given in accordance with the provisions of this Subscription Agreement. The parties agree that the determination of the arbitrators shall be binding and
conclusive upon them. 
 14. Blue Sky Qualification. The purchase of Securities under this Subscription Agreement is expressly conditioned upon the
exemption from qualification of the offer and sale of the Securities from applicable federal and state securities laws. The Company shall not be required to qualify this transaction under the securities laws of any jurisdiction and, should
qualification be necessary, the Company shall be released from any and all obligations to maintain its offer, and may rescind any sale contracted, in the jurisdiction. 

15. Use of Pronouns. All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter, singular or plural
as the identity of the person or persons referred to may require. 
 16. Confidentiality. 

(a) The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company, not otherwise
properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate or disclose, except as may be required by law or for the performance of this Subscription Agreement, or use to the detriment of the Company
or for the benefit of any other person or persons, or misuse in any way, any confidential information of the Company, including any scientific, technical, trade or business secrets of the Company and any scientific, technical, trade or business
materials that are treated by the Company as confidential or proprietary, including, but not limited to, ideas, discoveries, inventions, developments and improvements belonging to the Company and confidential information obtained by or given to the
Company about or belonging to third parties. 
 (b) The Purchaser acknowledges and agrees that certain information provided by the Company in
connection with the Offering may constitute material non-public information under United States or other applicable securities laws, and that the receipt of such information, if deemed to be material non-public information, may restrict the Purchaser’s ability to trade in securities of the Company, including but not limited to the Subscribed Shares, the Warrant Shares or any other shares of Common Stock of
the Company, until such time as the information is made public. The Company undertakes no obligation to make public disclosure of such information at any time, other than as may be required under applicable United States securities laws. 

(c) The provisions of this Section 16 are in addition to, and do not supersede or replace, the Purchaser’s obligations under any non-disclosure or confidentiality agreement previously entered into by the Purchaser with the Company. 

  
 10 

 17. Miscellaneous. 

(a) Except as otherwise expressly provided herein, this Subscription Agreement constitutes the entire agreement between the Purchaser and the
Company with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings, if any, relating to the subject matter hereof. The terms and provisions of this Subscription Agreement may be waived, or
consent for the departure therefrom granted, only by a written document executed by the party entitled to the benefits of such terms or provisions. 

(b) The representations and warranties of the Company and the Purchaser made in this Subscription Agreement shall survive the execution and
delivery hereof and delivery of the Subscribed Shares and the Warrants. 
 (c) Each of the parties hereto shall pay its own fees and expenses
(including the fees of any attorneys, accountants, appraisers or others engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the transactions contemplated hereby are
consummated. 
 (d) This Subscription Agreement may be executed in one or more counterparts each of which shall be deemed an original, but
all of which shall together constitute one and the same instrument. 
 (e) Each provision of this Subscription Agreement shall be considered
separable and, if for any reason any provision or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair the operation of or affect the remaining portions of this Subscription
Agreement. 
 (f) Section titles are for descriptive purposes only and shall not control or alter the meaning of this Subscription Agreement
as set forth in the text. 
 (g) The Purchaser understands and acknowledges that there may be multiple closings for this Offering. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 11 

 PRIVATE PLACEMENT OFFERING OF 

CYTODYN INC. 

SUBSCRIPTION INSTRUCTIONS 
 To
subscribe for Securities in the private offering of CytoDyn Inc.: 
  

	1.	 Date and Fill in the number of Securities being purchased and Complete and Sign one (1) copy
of the Subscription Agreement. 

  

	2.	 Initial the Accredited Investor Certification page attached to the Subscription Agreement.

  

	3.	 [intentionally omitted] 

 

	4.	 E-mail all forms to Antonio Migliarese at
amigliarese@cytodyn.com and then send all signed original documents to: 

 CytoDyn Inc. 

111 Main Street, Suite 660 

Vancouver, WA 98660 

Attention: Antonio Migliarese 

(360) 980-8524 
  

	5.	 Please wire funds directly to the Company pursuant to the following instructions (unless other arrangements
have been made): 

 Bank Name:       JPMorgan Chase Bank, N.A. 

Bank Address:   OR1-2013, 4155 Mercantile Drive, Lake Oswego, Oregon 97035 

ABA Number:   XXXXXXXXX 

A/C Name:         CytoDyn Inc. 

A/C Number:     XXXXXXXXX 

FBO:    Investor
Name                                         
                     

              Address       
                                         
                             

 CYTODYN INC. 

SIGNATURE PAGE TO THE 

SUBSCRIPTION AGREEMENT 
 Subscriber
hereby elects to subscribe under the Subscription Agreement for a total of 
 (1) ______________ Subscribed Shares with an aggregate purchase price of
$ _____________5 and 
 (2) Warrants exercisable for ______________6 shares of Common Stock. 
 (NOTE: to be completed by subscriber) and executes the Subscription
Agreement. 
 If the Purchaser is an INDIVIDUAL, and if purchased as JOINT TENANTS, as TENANTS IN COMMON, or as COMMUNITY PROPERTY: 

 
  

					
	  
	    	  
	    	
	Print Name(s)	    	Social Security Number(s)	    	
	  
	    	  
	    	
	Signature(s) of Subscriber(s)	    	Signature	    	
	  
	    	  
	    	
	Date	    	Address	    	

 If the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST: 

 

							
	  
 Name of
Partnership,
	  	  
 Federal Taxpayer
	  	
	Corporation, Limited	  	Identification Number	  	
	Liability Company or Trust	  		  	
				
	By:	 	  
	  	  
	  	
		 	Name:	  	State of Organization	  	
		 	Title:	  		  	
			
	  
 Date
	  	  
 Address
	  	

 Accepted and agreed: 

CYTODYN INC. 
  

					
	By:                                     
                                         
        	  	                                      
                                         
        	  	
	Authorized Officer	  	Date	  	

  
  

 

	5 	 To be equal to the product of (i) the number of Subscribed Shares and (ii) $1.00. 

	6 	 To be equal to 25% of the number of Subscribed Shares in Item 1. 

 CYTODYN INC. 

ACCREDITED INVESTOR CERTIFICATION 

For Individual Investors Only 

(all Individual Investors must INITIAL where appropriate): 

 

			
	Initial _______	  	I have an individual net worth, or joint net worth with my spouse, as of the date hereof in excess of $1 million. For purposes of calculating net worth under this category, (i) the undersigned’s primary residence
shall not be included as an asset, (ii) indebtedness that is secured by the undersigned’s primary residence, up to the estimated fair market value of the primary residence at the time of the sale of securities, shall not be included as a
liability, (iii) to the extent that the indebtedness that is secured by the primary residence is in excess of the fair market value of the primary residence, the excess amount shall be included as a liability, and (iv) if the amount of
outstanding indebtedness that is secured by the primary residence exceeds the amount outstanding 60 days prior to the execution of this Subscription Agreement, other than as a result of the acquisition of the primary residence, the amount of such
excess shall be included as a liability.
		
	Initial _______	  	I have had an annual gross income for the past two years of at least $200,000 (or $300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.
		
	Initial _______	  	I am a director or executive officer of CytoDyn Inc.
		
	Initial _______	  	I hold in good standing a Series 7, 65 or 82 license.

 For Non-Individual Investors 

(all Non-Individual Investors must INITIAL where appropriate): 

 

			
	Initial _______	  	The investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above.
		
	Initial _______	  	The investor certifies that it is a partnership, corporation, limited liability company or any organization described in Section 501(c)(3) of the Internal Revenue Code, Massachusetts or similar business trust that has total
assets of at least $5,000,000 and was not formed for the purpose of investing in the Company.
		
	Initial _______	  	The investor certifies that it is an employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a
bank, savings and loan association, insurance company or registered investment adviser.

			
	Initial _______	  	The investor certifies that it is an employee benefit plan whose total assets exceed $5,000,000 as of the date of this Subscription Agreement.
		
	Initial _______	  	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet any of the criteria for Individual Investors.
		
	Initial _______	  	The investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.
		
	Initial _______	  	The investor certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
		
	Initial _______	  	The investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding $5,000,000 and not formed for the specific purpose of investing in the Company.
		
	Initial _______	  	The investor certifies that it is a trust with total assets of at least $5,000,000, not formed for the specific purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in
financial and business matters that he is capable of evaluating the merits and risks of the prospective investment.
		
	Initial _______	  	The investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of
$5,000,000.
		
	Initial _______	  	The investor certifies that it is an insurance company as defined in §2(13) of the Securities Act, or a registered investment company.
		
	Initial _______	  	The investor certifies that it is an investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act.
		
	Initial _______	  	The investor certifies that it is a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958.
		
	Initial _______	  	The investor certifies that it is a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.

 EXHIBIT A 

FORM OF WARRANTEX-10.2

 Exhibit 10.2 

WARRANT EXERCISE INDUCEMENT AGREEMENT 

This Warrant Exercise Inducement Agreement (this “Agreement”), dated as of _______, 2021, is by and between CytoDyn Inc., a
Delaware corporation, (the “Company”) and the undersigned holder (the “Holder”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”),
issued by the Company, as set forth on Schedule A (collectively, the “Warrants”). 
 WITNESSETH: 

WHEREAS, the Holder’s Warrants are exercisable into a number of shares of Common Stock as set forth on Schedule A (the
“Warrant Shares”); and 
 WHEREAS, as an additional inducement to the Holder to exercise the Warrants, the Company
will (i) increase the number of shares of Common Stock issuable upon exercise of the Warrants by one hundred percent (100%), such that each Warrant covers two (2) times the stated number of shares currently covered by the Warrant (such
shares, the “Additional Shares”) and (ii) increase the stated exercise price of each Warrant by one hundred percent (100%), such that the exercise price is equal to two (2) times the existing exercise price. 

NOW, THEREFORE, for and in consideration of the mutual covenants contained herein, the receipt and sufficiency of which is hereby
acknowledged, the Company and the Holder hereby agree as follows: 
 1. Exercise of Warrants. The Company and the Holder hereby agree
that the Holder shall exercise the Warrants in full at an exercise price equal to two (2) times the original Warrant exercise price, for aggregate cash proceeds to the Company set forth on Schedule A, with all other
terms of the Warrants being unchanged. The Warrant Shares and the Additional Shares as set forth on Schedule A will be delivered to the Holder upon the Closing to the name and address set forth on the signature page hereof. 

2. Closing; Payment. Holder shall execute this Agreement and immediately wire the aggregate cash exercise price for the Warrants listed
on Schedule A to the following bank account: 
  

			
	 Bank Name:
	  	 JPMorgan Chase Bank, N.A.

	 Bank Address:
	  	 Business Banking, OR1-2013

		  	 4155 Mercantile Drive

		  	 Lake Oswego, Oregon 97035

	 ABA Number:
	  	 XXXXXXXXX

	 A/C Name:
	  	 CytoDyn Inc.

	 A/C Number:
	  	 XXXXXXXXX

	 FBO:
	  	                                      
                      
		  	 See Schedule A

 The closing of the exercise of the Warrants and the issuance of the Warrant Shares and Additional Shares (the
“Closing”) shall occur following execution by the Company and delivery to the Holder of an executed copy of this Agreement, against receipt of such aggregate cash exercise price. The Closing may be scheduled by the Company at any
time within seven (7) calendar days after the execution by the Company of this Agreement (such date, the “Closing Date”). To the extent the Closing does not occur, all funds received from the Holder will be returned without
interest or offset, and this Agreement shall thereafter be of no further force or effect. 

  
 1 

 3. Restrictions on Transfer of Securities. 

(a) Restricted Securities. The Warrant Shares, if not previously registered through a registered direct offering for which such
registration statement is currently effective, and the Additional Shares will be “restricted securities” upon issuance to the Holder hereunder. Restricted securities may not be sold by the holder absent registration, or an exemption from
the registration requirements, under the Securities Act of 1933, as amended (the “Securities Act”), or the applicable securities laws of any other state or jurisdiction. 

(b) Registered Shares. The Company has previously filed Registration Statements on
Form S-3 (the “Resale Registration Statements”), as listed on Schedule A, to register the resale of some of the Warrant Shares under the Securities Act. Promptly following the
Closing, the Company intends to file a Current Report on Form 8-K to reflect the substantive changes from the information currently set forth in the prospectus included in such Resale Registration
Statements as a result of the transactions contemplated by this Agreement. Thereafter, if Holder is named as selling stockholder in a Resale Registration Statement, Holder may sell the Warrant Shares in accordance with the resale provisions set
forth in the “Plan of Distribution” section of the applicable Resale Registration Statement prospectus. Holder should read the applicable Registration Statement prospectus carefully before deciding whether to enter into this Agreement.

 (c) Restrictive Legends. The Holder understands and agrees that the Additional Shares, are not, and will not be, registered under
the Securities Act; accordingly, the Additional Shares must be held indefinitely unless, in the opinion of counsel reasonably acceptable to the Company, a sale or transfer may be made in compliance with the provisions of this Agreement and without
registration under United States securities laws and the applicable securities laws of any state or other jurisdiction. Legends will be placed on the Additional Shares, and appropriate notations will be made in the Company’s stock books and
stop transfer instructions placed with the transfer agent of the Common Stock, each in a manner generally consistent with the foregoing. 

4. Representations and Warranties. The Holder hereby acknowledges, represents, warrants, and agrees as follows: 

(a) The Holder is an “accredited investor” as defined in Regulation D promulgated under the Securities Act, as shown in the
Accredited Investor Certification attached to this Agreement. The Holder, alone or together with his, her or its representatives, has such knowledge, sophistication, and experience in business and financial matters as to be capable of evaluating the
merits and risks of the prospective investment in the Warrant Shares and Additional Shares, and has so evaluated the merits and risks of such investment. The Holder has reviewed the Company’s
Form 10-K for the year ended May 31, 2021, and all filings made by the Company with the U.S. Securities and Exchange Commission (the “SEC”) thereafter. The Holder has also been
afforded the opportunity to ask questions of, and receive answers from, the officers and directors of the Company concerning the terms and conditions of the Warrant Shares and Additional Shares and the information filed with the SEC and to obtain
any additional information, to the extent that the Company possesses such information, which the Holder considers necessary and appropriate in order to permit the Holder to evaluate the merits and risks of an investment in the Warrant Shares and
Additional Shares. The Holder is able to bear the economic risk of an investment in the Warrant Shares and Additional Shares and, at the present time, is able to afford a complete loss of such investment. The Holder is not acquiring the Warrant
Shares or Additional Shares for the account or benefit of any other person. The Holder is acquiring the Warrant Shares and Additional Shares as 

  
 2 

 
principal for his, her or its own account, in the ordinary course of business, and not with a view to or for distributing or reselling such Warrant Shares (other than Warrant Shares subject to a
Resale Registration Statement) or Additional Shares or any part thereof. The Holder has no present intention of distributing any of such Warrant Shares (except as provided in the preceding sentence) or Additional Shares and has no agreement or
understanding, directly or indirectly, with any person regarding the distribution of such Warrant Shares or Additional Shares as to which this sentence applies. 

(b) Neither the SEC nor any state securities commission or other regulatory authority has approved the Additional Shares, or passed upon or
endorsed the merits of this offering of securities or confirmed the accuracy or determined the adequacy of such offering. This offering of securities has not been reviewed by any federal, state or other regulatory authority. 

(c) The Holder is aware of the provisions of Rule 144 which, in substance, permit limited public resale of “restricted securities”
acquired by non-affiliates of the issuer thereof, directly or indirectly, from the issuer (or from an affiliate of such issuer), in a non-public offering subject to the
satisfaction of certain conditions, if applicable, including, among other things, the availability of certain public information about the Company and the resale occurring not less than six (6) months after the party has purchased and paid for
the securities to be sold. 
 (d) The Holder further understands that at the time the Holder wishes to sell Warrant Shares or Additional
Shares, there may be no public market upon which to make such a sale, and that, even if such a public market then exists, the Company may not have filed all reports and other materials (other than Form 8-K
reports) required under Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, during the preceding 12 months, and that, in such event, because the Company is a former “shell company” as contemplated under paragraph
(i) of Rule 144, Rule 144 will not be available to the Holder. 
 (e) The Holder further understands that, because the Company is a
former “shell company” as contemplated under paragraph (i) of Rule 144, regardless of the amount of time that the Holder holds the Warrant Shares and Additional Shares, sales of such securities may only be made under Rule 144 upon the
satisfaction of certain conditions, including that the Company has filed with the SEC, during the 12 months preceding the sale, all quarterly and annual reports required under the Securities Exchange Act of 1934, as amended; and that,
accordingly, any restrictive legends cannot be removed except in connection with an actual sale that is subject to an effective registration statement under, or an applicable exemption from the registration requirements of, the Securities Act,
and “blanket” removals of any such restrictive legends will not be possible. 
 (f) The Holder further understands that, in
the event all of the requirements of Rule 144 are not satisfied, registration under the Securities Act, compliance with Regulation A promulgated under the Securities Act, or some other registration exemption will be required; and that,
notwithstanding the fact that Rule 144 is not exclusive, the staff of the SEC has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rule 144 will have
a substantial burden of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. 

(g) Prior to the execution of this Agreement, the Holder and the Holder’s attorney, accountant, purchaser representative and/or tax
adviser, if any (collectively, the “Advisers”), have received all documents requested by the Holder, have carefully reviewed them and understand the information contained therein. 

  
 3 

 (h) All documents, records, and books pertaining to the investment in the Warrant Shares and
Additional Shares have been made available for inspection by such Holder and his, her or its Advisers, if any. 
 (i) The Holder and the
Holder’s Advisers, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or persons acting on behalf of the Company concerning this Agreement and the business, financial condition and results of
operations of the Company, and all such questions have been answered to the full satisfaction of the Holder and Advisers, if any. 
 (j) In
evaluating the suitability of an investment in the Company, the Holder has not relied upon any representation or information (oral or written) other than as stated in this Agreement. 

(k) The Purchaser has taken no action that would give rise to any claim by any person for brokerage commissions, finders’ fees or the
like relating to this Agreement or the transactions contemplated hereby. 
 (l) The Holder is aware that an investment in the Warrant Shares
and Additional Shares is high risk, involving a number of very significant risks and has carefully read and considered the matters set forth under the caption “Risk Factors” in the Company’s Form
10-K filed with the SEC on July 30, 2021, and, in particular, acknowledges that the Company (i) has significant operating losses since inception, no revenues to date, and limited assets, (ii) is
engaged in a highly competitive business and (iii) will need additional capital, resulting in dilution to the Holder if the Holder is not able to participate in future offerings. 

4. Reliance. The Holder acknowledges and understands that the Company has agreed to the terms of this Agreement in reliance upon the
Holder’s representations, warranties and covenants made in this Agreement. 
 5. Modification. This Agreement shall not be
modified or waived except by an instrument in writing signed by the party against whom any such modification or waiver is sought. 
 6.
Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, understandings, discussions and representations, oral or written, with respect
to such matters. 
 7. Governing Law. This Agreement shall be governed by, and construed in accordance with, the internal laws of the
State of New York, without giving effect to the principles of conflicts of law that would require the application of the laws of any other jurisdiction. 

8. Severability. In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the
validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. 

9. Successors. This Agreement shall be binding upon and inure to the benefit of the Holder and the Company and the respective
successors and permitted assigns of each. 
 10. Counterparts. This Agreement may be executed in two or more counterparts, each of
which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. 

  
 4 

 11. EXPIRATION DATE. THIS OFFER IS FOR A LIMITED TIME ONLY AND SHALL EXPIRE IF THE
SIGNATURE PAGE TO THIS AGREEMENT IS NOT COMPLETED, EXECUTED BY THE HOLDER AND RETURNED TO THE COMPANY ON OR BEFORE 5:00 P.M. EASTERN TIME ON ______________, 2021. 

[Signature page to follow.] 

  
 5 

 Please confirm that the foregoing correctly sets forth the agreement between us by signing in the space
provided below for that purpose. 
  

			
	 HOLDER

		
	 By:
	 	
         

 
			
	 Print Name:
	 	
         

 
			
	 Title:
	 	
 

			
	 Address:
	 	
 

			
	  

	 Email:
	 	
 

 

			
	 Agreed and Accepted:

	
	 CYTODYN INC.

		
	 By:
	 	
         

	 Name: Antonio Migliarese

	 Title: CFO

 Dated as of: ________________________ 

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00333-of-00352.parquet"}]]